UCB Unveils Key Research Advances at International Epilepsy Congress 2025
UCB Unveils Key Research Advances at International Epilepsy Congress 2025
UCB, a prominent global biopharmaceutical company, has made a significant impact at the International Epilepsy Congress (IEC) in Lisbon, Portugal, by presenting 26 scientific abstracts. Among these, two were featured as oral presentations, highlighting UCB's unwavering commitment to the advancement of epilepsy research and treatment.
Focusing on Developmental and Epileptic Encephalopathies
The presented data primarily concentrate on serious conditions such as Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), alongside emerging research surrounding prolonged seizures and their real-world implications. Dimitrios Bourikas, UCB's Global Medical Head of DEE and Epilepsy, emphasized the company's mission to improve care for individuals living with epilepsy and the critical role insights from ongoing research play in driving innovations that cater to actual patient needs.
Highlights From the IEC Presentations
1. Fenfluramine Open-Label Extension Study: A substantial open-label extension study enrolling 412 patients with DS or LGS yielded promising results. Safety signals were consistent with earlier studies, and data showed sustained benefits over the long term, reaffirming fenfluramine's role in managing these severe epileptic conditions.
2. Challenges in Diagnosing DEEs in Adults: A qualitative research initiative engaged caregivers and healthcare professionals in the UK, Germany, France, and Spain, outlining the barriers to diagnosing developmental and epileptic encephalopathies in adults. Participants noted that a confirmed diagnosis enables a more comprehensive treatment approach, which can improve patient quality of life.
3. Impact of Unpredictable Seizures on Caregivers: An anonymous survey demonstrated the burden placed on caregivers, with approximately half reporting that disruptive seizures resulted in observable changes in quality of life and temporary loss of essential functions.
4. Defining Prolonged Seizures: Research characterizing prolonged seizure events highlights significant unmet needs for patients and caregivers, notably indicating how these incidences can escalate to emergency situations, leading to hospitalizations.
5. The Medication Landscape for Seizure Emergencies: A global analysis reviewed the availability and insurance coverage of acute seizure medications based on patient settings. This insight aims to improve access to necessary treatments, particularly for outpatient care.
UCB's Commitment to Patient-Centric Solutions
The breadth of findings presented emphasizes UCB's dedication to enhancing understanding of epilepsy and improving patient outcomes. By fostering knowledge, encouraging conversations on seizure emergencies, and devising improved pathways for diagnosis and treatment, UCB strives to be at the forefront of reshaping how epilepsy is understood and treated.
Furthermore, the company will host a symposium on September 1, titled “Time Matters in Developmental and Epileptic Encephalopathies,” targeting improved awareness regarding the multifaceted impacts of DEEs on adult patients. Managing patient care beyond merely controlling seizures is crucial for optimizing outcomes.
Conclusion
UCB’s presentation of cutting-edge research at the International Epilepsy Congress marks a pivotal moment in understanding and addressing the challenges faced by those living with epilepsy. By dedicating resources and expertise towards innovations that define patient experiences, UCB is setting a benchmark in the pursuit of better care and improved quality of life for affected individuals and families.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.